141 related articles for article (PubMed ID: 32953425)
1. Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada.
Gilca R; Billard MN; Zafack J; Papenburg J; Boucher FD; Charest H; Rochette M; De Serres G
Prev Med Rep; 2020 Dec; 20():101180. PubMed ID: 32953425
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Bjornson C; Chan P; Li A; Paes B; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants.
Wu P; Escobar GJ; Gebretsadik T; Carroll KN; Li SX; Walsh EM; Mitchel EF; Sloan C; Dupont WD; Yu C; Horner JR; Hartert TV
Am J Epidemiol; 2018 Jul; 187(7):1490-1500. PubMed ID: 29351636
[TBL] [Abstract][Full Text] [Related]
5. Summary of the National Advisory Committee on Immunization (NACI) statement update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants.
Moore D; Sinilaite A; Killikelly A
Can Commun Dis Rep; 2022 Jul; 48(7-8):363-366. PubMed ID: 37426290
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and ethical issues: experiences and concerns of healthcare workers regarding a new RSV prophylaxis programme in Nunavik, Quebec.
Lorcy A; Gilca R; Dubé E; Rochette M; De Serres G
Int J Circumpolar Health; 2020 Dec; 79(1):1742564. PubMed ID: 32191589
[No Abstract] [Full Text] [Related]
7. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
8. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada.
Nourbakhsh S; Shoukat A; Zhang K; Poliquin G; Halperin D; Sheffield H; Halperin SA; Langley JM; Moghadas SM
EClinicalMedicine; 2021 Nov; 41():101141. PubMed ID: 34622186
[TBL] [Abstract][Full Text] [Related]
10. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.
Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B;
Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab Prophylaxis for infants 29 to 32 weeks gestation at birth: A 10-year audit from Vancouver Island using BC Guidelines.
Taylor RS; Baker MH
Paediatr Child Health; 2021; 26(2):e110-e114. PubMed ID: 36381679
[TBL] [Abstract][Full Text] [Related]
13. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus.
Buchs C; Dalphin ML; Sanchez S; Perceval M; Coutier L; Mainguy C; Kassaï-Koupaï B; Reix P
Eur J Pediatr; 2017 Jul; 176(7):891-897. PubMed ID: 28508992
[TBL] [Abstract][Full Text] [Related]
15. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
16. RSV Hospitalizations in Comparison With Regional RSV Activity and Inpatient Palivizumab Administration, 2010-2013.
Glick AF; Kjelleren S; Hofstetter AM; Subramony A
Hosp Pediatr; 2017 May; 7(5):271-278. PubMed ID: 28381595
[TBL] [Abstract][Full Text] [Related]
17. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
19. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
